The challenges of full-dose psychedelics
While psychedelics appear to have considerable potential benefits and low physiological risks [full-dose experiences can put participants under considerable psychological buy shrooms risk In a survey targeting participants that had at least one challenging experience (“bad trip”) with psilocybin mushrooms, 39% of respondents rated their full-dose experiences as among the top 5 most psychologically difficult/challenging experiences of their lives . Griffiths et al. [used both “high” (22 mg/70 kg) and “low” (1 or 3 mg/70 kg) doses of psilocybin as experimental and control conditions, respectively. A dose-response effect could be seen such that in the high-dose condition, 32% of participants reported physiological discomfort whereas only 12% reported the same in the low-dose condition; likewise, 26% reported anxiety in the high-dose condition versus 15% in the low-dose condition [Delayed-onset headaches are another possible side-effect of full-dose psilocybin [
To mitigate these risks, Johnson et al.] proposed safety guidelines for use with full-dose psychedelic substances, which rely on managing participant inclusion and having a comfortable, guided clinical setting. As microdosing does not involve the intensity of experience present in full-dose research, challenging experiences may be less likely. One may, however, anticipate that less frequent, less intense versions of full-dose challenges could be present even at the very low doses used in microdosing (e.g. restlessness instead of insomnia, mild anxiety instead of fear, mild headaches). As the study of microdosing is in its infancy, we could also expect there to be challenges that fall beyond the scope of reports based on full doses; the present study thus preferred open-ended surveying of drawbacks over pre-existing focal questionnaires.